AU2012295390B2 - Concentrated felbamate formulations for parenteral administration - Google Patents

Concentrated felbamate formulations for parenteral administration Download PDF

Info

Publication number
AU2012295390B2
AU2012295390B2 AU2012295390A AU2012295390A AU2012295390B2 AU 2012295390 B2 AU2012295390 B2 AU 2012295390B2 AU 2012295390 A AU2012295390 A AU 2012295390A AU 2012295390 A AU2012295390 A AU 2012295390A AU 2012295390 B2 AU2012295390 B2 AU 2012295390B2
Authority
AU
Australia
Prior art keywords
composition
felbamate
agent
solution
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012295390A
Other languages
English (en)
Other versions
AU2012295390A1 (en
Inventor
Sasha H. Bakhru
Bryan E. Laulicht
Edith Mathiowitz
Solomon S. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perosphere Pharmaceuticals Inc
Original Assignee
Perosphere Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perosphere Pharmaceuticals Inc filed Critical Perosphere Pharmaceuticals Inc
Publication of AU2012295390A1 publication Critical patent/AU2012295390A1/en
Application granted granted Critical
Publication of AU2012295390B2 publication Critical patent/AU2012295390B2/en
Assigned to PEROSPHERE PHARMACEUTICALS INC. reassignment PEROSPHERE PHARMACEUTICALS INC. Request to Amend Deed and Register Assignors: PEROSPHERE INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012295390A 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration Ceased AU2012295390B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522811P 2011-08-12 2011-08-12
US61/522,811 2011-08-12
PCT/US2012/050148 WO2013025442A2 (en) 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration

Publications (2)

Publication Number Publication Date
AU2012295390A1 AU2012295390A1 (en) 2014-03-13
AU2012295390B2 true AU2012295390B2 (en) 2015-12-24

Family

ID=47715640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012295390A Ceased AU2012295390B2 (en) 2011-08-12 2012-08-09 Concentrated felbamate formulations for parenteral administration

Country Status (7)

Country Link
US (2) US20140178479A1 (OSRAM)
EP (1) EP2741751A4 (OSRAM)
JP (3) JP2014525402A (OSRAM)
AU (1) AU2012295390B2 (OSRAM)
CA (1) CA2844907A1 (OSRAM)
HK (1) HK1198942A1 (OSRAM)
WO (1) WO2013025442A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3202898T3 (en) 2009-11-02 2019-01-14 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
WO2015100252A1 (en) * 2013-12-23 2015-07-02 Perosphere, Inc. Deuterated felbamate, compositions containing the same, and methods of use thereof
GB201604359D0 (en) * 2016-03-15 2016-04-27 Univ Newcastle Treatment of tissue disorders
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
WO2007041524A2 (en) * 2005-09-30 2007-04-12 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
US20090311325A1 (en) * 2006-04-10 2009-12-17 K.U.Leuven Research And Development Enhancing solubility and dissolution rate of poorly soluble drugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1904257A (en) * 1926-10-29 1933-04-18 Firm Of Chemical Works Formerl Supersaturated calcium gluconate solution
US3017323A (en) * 1957-07-02 1962-01-16 Pfizer & Co C Therapeutic compositions comprising polyhydric alcohol solutions of tetracycline-type antibiotics
US5308621A (en) * 1991-02-18 1994-05-03 Commonwealth Scientific And Industrial Research Organisation Ascorbic acid composition and transdermal administration method
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
ATE244564T1 (de) * 1999-02-09 2003-07-15 Univ Virginia Felbamat-derivate
ES2303527T3 (es) * 2000-05-10 2008-08-16 Jagotec Ag Procedimiento de molienda.
MXPA04009968A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US7259153B2 (en) * 2003-02-03 2007-08-21 Supernus Pharmaceuticals Drug formulation and delivery using crystalline methylated cyclodextrins
US20060160776A1 (en) * 2003-05-28 2006-07-20 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
CA2637359A1 (en) * 2006-01-17 2007-07-26 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions
US20120053220A1 (en) * 2007-08-02 2012-03-01 The General Hospital Corporation D/B/A Massachusetts General Hospital Novel lipoxygenase inhibitors as neuroprotective agents
EP2273993A4 (en) * 2008-04-01 2011-06-15 Univ Colorado Regents METHOD AND COMPOSITIONS FOR THE INTRA-CEREBRUCTIVE ADMINISTRATION OF FELBAMATE
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CN103635179B (zh) * 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
WO2007041524A2 (en) * 2005-09-30 2007-04-12 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
US20090311325A1 (en) * 2006-04-10 2009-12-17 K.U.Leuven Research And Development Enhancing solubility and dissolution rate of poorly soluble drugs

Also Published As

Publication number Publication date
US20170157083A1 (en) 2017-06-08
JP2019085416A (ja) 2019-06-06
HK1198942A1 (en) 2015-06-19
US20140178479A1 (en) 2014-06-26
CA2844907A1 (en) 2013-02-21
JP2017122127A (ja) 2017-07-13
EP2741751A2 (en) 2014-06-18
WO2013025442A2 (en) 2013-02-21
WO2013025442A3 (en) 2013-04-25
EP2741751A4 (en) 2015-03-25
AU2012295390A1 (en) 2014-03-13
JP2014525402A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
US20170157083A1 (en) Concentrated felbamate formulations for parenteral administration
US20240307542A1 (en) Pharmaceutical Compositions Having Improved Storage Stability
JP2025128183A (ja) てんかん性障害の処置のための方法および組成物
US9770414B2 (en) Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US20100062066A1 (en) Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
CN107970208B (zh) 一种丁苯酞注射液及其制备方法
US8299124B2 (en) Aqueous intraocular penetration-promoting eye drop
US7758890B2 (en) Treatment using dantrolene
KR20110005798A (ko) 활성 일산화질소 공여체 및 그 제조 및 사용 방법
PT100850B (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
SK112795A3 (en) Parenterally applicable stable medicaments
CA2830511C (en) Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate
JP2009541484A (ja) ５ｈｔ６モジュレーターおよびコリンエステラーゼインヒビターを含む組み合わせ
JP6535338B2 (ja) 新規製剤
JP6934581B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
JP2024512310A (ja) 低吸着グリブリド製剤および方法
EP1603513B1 (en) Dantrolene compositions
US11752165B2 (en) Basic chemotherapeutic intratumour injection formulation
US20060276436A1 (en) Farnesyl dibenzodiazepinone formulation
MX2008010394A (es) Tratamientos antivirales intravenosos.
JPH06263636A (ja) 脳または高次神経疾患治療剤
AU2018390274C1 (en) Therapeutic agent for glaucoma comprising FP agonist and β blocker
HK1047704A1 (en) New use of a macrolide compound
JP2023510173A (ja) 中枢神経系障害の処置及び防止のための化合物
JP2024090829A (ja) 滅菌容器に収容されるエピナスチン含有水性医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: PEROSPHERE PHARMACEUTICALS INC.

Free format text: FORMER NAME(S): PEROSPHERE INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired